-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting JATT Acquisition (NYSE:JATT) and Novavax (NASDAQ:NVAX)
Contrasting JATT Acquisition (NYSE:JATT) and Novavax (NASDAQ:NVAX)
Novavax (NASDAQ:NVAX – Get Rating) and JATT Acquisition (NYSE:JATT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Profitability
This table compares Novavax and JATT Acquisition's net margins, return on equity and return on assets.
Get Novavax alerts:Net Margins | Return on Equity | Return on Assets | |
Novavax | -114.32% | -572.54% | -55.69% |
JATT Acquisition | N/A | -105.35% | 6.64% |
Insider & Institutional Ownership
42.6% of Novavax shares are held by institutional investors. Comparatively, 44.8% of JATT Acquisition shares are held by institutional investors. 2.1% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Novavax and JATT Acquisition's top-line revenue, earnings per share (EPS) and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Novavax | $1.15 billion | 1.46 | -$1.74 billion | ($19.46) | -1.10 |
JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
JATT Acquisition has lower revenue, but higher earnings than Novavax.
Analyst Ratings
This is a breakdown of recent recommendations for Novavax and JATT Acquisition, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Novavax | 2 | 0 | 5 | 0 | 2.43 |
JATT Acquisition | 0 | 0 | 0 | 0 | N/A |
Novavax currently has a consensus price target of $128.25, indicating a potential upside of 497.07%. Given Novavax's higher possible upside, equities research analysts clearly believe Novavax is more favorable than JATT Acquisition.
Summary
JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.
About Novavax
(Get Rating)
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
About JATT Acquisition
(Get Rating)
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
Novavax (NASDAQ:NVAX – Get Rating) and JATT Acquisition (NYSE:JATT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
諾華(納斯達克:NVAX-GET評級)和JATT收購(紐約證券交易所:JATT-GET評級)都是小盤醫療公司,但哪種投資更好?我們將根據這兩家公司的收益、機構所有權、估值、盈利能力、風險、分析師建議和股息的實力進行比較。
Profitability
盈利能力
This table compares Novavax and JATT Acquisition's net margins, return on equity and return on assets.
此表比較了Novavax和JATT收購的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Novavax | -114.32% | -572.54% | -55.69% |
JATT Acquisition | N/A | -105.35% | 6.64% |
淨利潤率 | 股本回報率 | 資產回報率 | |
諾華 | -114.32% | -572.54% | -55.69% |
JATT收購 | 不適用 | -105.35% | 6.64% |
Insider & Institutional Ownership
內部人與機構所有權
42.6% of Novavax shares are held by institutional investors. Comparatively, 44.8% of JATT Acquisition shares are held by institutional investors. 2.1% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Novavax 42.6%的股份由機構投資者持有。相比之下,JATT收購股份的44.8%由機構投資者持有。Novavax 2.1%的股份由公司內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一隻股票有望實現長期增長。
Valuation & Earnings
估值與收益
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Novavax | $1.15 billion | 1.46 | -$1.74 billion | ($19.46) | -1.10 |
JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
諾華 | 11.5億美元 | 1.46 | -17.4億美元 | ($19.46) | -1.10 |
JATT收購 | 不適用 | 不適用 | 685萬美元 | 不適用 | 不適用 |
JATT Acquisition has lower revenue, but higher earnings than Novavax.
Jatt收購的收入低於Novavax,但收益高於Novavax。
Analyst Ratings
分析師評級
This is a breakdown of recent recommendations for Novavax and JATT Acquisition, as provided by MarketBeat.
這是MarketBeat提供的最近對Novavax和JATT收購建議的細分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Novavax | 2 | 0 | 5 | 0 | 2.43 |
JATT Acquisition | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
諾華 | 2 | 0 | 5 | 0 | 2.43 |
JATT收購 | 0 | 0 | 0 | 0 | 不適用 |
Novavax currently has a consensus price target of $128.25, indicating a potential upside of 497.07%. Given Novavax's higher possible upside, equities research analysts clearly believe Novavax is more favorable than JATT Acquisition.
諾華目前的一致目標價為128.25美元,表明潛在漲幅為497.07%。考慮到Novavax更有可能的上行空間,股票研究分析師顯然認為Novavax比JATT的收購更有利。
Summary
摘要
JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.
Jatt收購在兩隻股票之間的9個因素中有5個擊敗了Novavax。
About Novavax
關於Novavax
(Get Rating)
(獲取評級)
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax,Inc.是一家生物技術公司,專注於疫苗的發現、開發和商業化,以預防嚴重的傳染病和滿足衞生需求。該公司的候選疫苗包括冠狀病毒候選疫苗NVX-CoV2373,它正在進行兩項第三階段試驗、一項IIb階段試驗和一項I/II階段試驗;NanoFlu,一種處於第三階段臨牀試驗的季節性四價流感疫苗候選產品;以及ResVax,一種呼吸道合胞病毒(RSV)融合(F)蛋白質納米顆粒疫苗候選產品。它還在開發針對老年人(60歲及以上)的第二階段臨牀試驗的RSV F疫苗,以及針對兒科的第一階段臨牀試驗。它與武田藥品株式會社就新冠肺炎候選疫苗NVX-CoV2373的開發、製造和商業化達成了一項合作協議。Novavax公司成立於1987年,總部設在馬裏蘭州蓋瑟斯堡。
About JATT Acquisition
關於JATT收購
(Get Rating)
(獲取評級)
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
Jatt Acquisition Corp沒有重大業務。擬與一個或者多個企業或者實體進行合併、股本置換、資產收購、股份購買、重組或者類似的業務合併。該公司打算專注於主要在生命科學領域運營的業務。Jatt收購公司成立於2021年,總部設在開曼羣島的大開曼羣島。
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
接受Novavax Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Novavax和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧